Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Alzamend Neuro, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −2 vs. Q4 2023
- Shares held
- 387.1K
- +12.8K (+3.4%) vs. Q4 2023
- Total value
- $386.8K
- +$52.1K (+15.6%) vs. Q4 2023
- New holders
- 1
- 3 more added
- Sold out
- 3
- 0 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $3.26M |
| Q1 2026 | 13 | $723.1K |
| Q4 2025 | 13 | $447.2K |
| Q3 2025 | 11 | $351.3K |
| Q2 2025 | 7 | $6.36K |
| Q1 2025 | 11 | $59.9K |
| Q4 2024 | 17 | $131.7K |
| Q3 2024 | 12 | $71.2K |
| Q2 2024 | 16 | $150.5K |
| Q1 2024 | 13 | $386.8K |
| Q4 2023 | 16 | $334.7K |
| Q3 2023 | 27 | $1.49M |
| Q2 2023 | 24 | $3.13M |
| Q1 2023 | 26 | $2.64M |
| Q4 2022 | 33 | $3.98M |
| Q3 2022 | 17 | $9.41M |
| Q2 2022 | 21 | $2.70M |
| Q1 2022 | 22 | $4.01M |
| Q4 2021 | 20 | $1.66M |
| Q3 2021 | 17 | $1.99M |
| Q2 2021 | 11 | $2.58M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Alzamend Neuro, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Truist Financial Corp | 154,327 | $154.3K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 78,545 | $78.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 52,397 | $52.4K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 39,740 | $39.7K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 26,482 | $26.0K | 0.00% | +26,482 | New |
| RFG Advisory, LLC | 16,666 | $16.7K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,790 | $14.0K | 0.00% | +3,600+35.3% | Added |
| Tower Research Capital LLC (TRC) | 4,747 | $4.75K | 0.00% | +1,431+43.2% | Added |
| Harbor Investment Advisory, LLC | 200 | $200 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 66 | $66 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 39 | $39 | 0.00% | +4+11.4% | Added |
| Morgan Stanley | 33 | $33 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 33 | $33 | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −16,806−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,909−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Baystate Wealth Management LLC | – | – | – | – | Not filed |